| 000 | 01864 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516223649.0 | ||
| 264 | 0 | _c20150514 | |
| 008 | 201505s 0 0 eng d | ||
| 022 | _a1531-8257 | ||
| 024 | 7 |
_a10.1002/mds.25961 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBorgohain, Rupam | |
| 245 | 0 | 0 |
_aTwo-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. _h[electronic resource] |
| 260 |
_bMovement disorders : official journal of the Movement Disorder Society _cSep 2014 |
||
| 300 |
_a1273-80 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAlanine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBenzylamines _xtherapeutic use |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDyskinesia, Drug-Induced |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInternational Cooperation |
| 650 | 0 | 4 |
_aLevodopa _xtherapeutic use |
| 650 | 0 | 4 | _aLongitudinal Studies |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSzasz, Jozsef | |
| 700 | 1 | _aStanzione, Paolo | |
| 700 | 1 | _aMeshram, Chandrashekhar | |
| 700 | 1 | _aBhatt, Mohit H | |
| 700 | 1 | _aChirilineau, Dana | |
| 700 | 1 | _aStocchi, Fabrizio | |
| 700 | 1 | _aLucini, Valentina | |
| 700 | 1 | _aGiuliani, Rodolfo | |
| 700 | 1 | _aForrest, Emma | |
| 700 | 1 | _aRice, Patricia | |
| 700 | 1 | _aAnand, Ravi | |
| 773 | 0 |
_tMovement disorders : official journal of the Movement Disorder Society _gvol. 29 _gno. 10 _gp. 1273-80 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/mds.25961 _zAvailable from publisher's website |
| 999 |
_c24025968 _d24025968 |
||